RT Journal Article
SR Electronic
T1 Seroprevalence of SARS-CoV-2 in Palestine: a cross-sectional seroepidemiological study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.28.20180083
DO 10.1101/2020.08.28.20180083
A1 Nouar Qutob
A1 Faisal Awartani
A1 Zaidoun Salah
A1 Mohammad Asia
A1 Imad Abu Khader
A1 Khaled Herzallah
A1 Nadeen Balqis
A1 Husam Sallam
YR 2020
UL http://medrxiv.org/content/early/2020/09/02/2020.08.28.20180083.abstract
AB Seroprevalence rates are important indicators to the epidemiology of COVID-19 and the extent of the pandemic given the existence of asymptomatic cases. The purpose of this study is to assess the seroprevalence rate in the Palestinian population residing in the West Bank. Blood samples were collected between 15th June 2020 and 30th June 2020 from 1355 individuals from randomly selected households in the West Bank in addition to 1136 individuals visiting Palestinian medical laboratories between the 1st May 2020 and 9th July 2020 for a routine checkup. Out of the 2491 blood samples collected, serological tests for 2455 adequate serum samples were done using an Immunoassay for qualitative detection of antibodies against SARS-CoV-2. The random sample of Palestinians living in the West Bank yielded 0% seroprevalence with 95% CI [0,0.0036], while the lab referrals sample yielded an estimated seroprevalence of 0.354% with 95% CI [0.0011,0096]. Our results indicate that as of July 2020, seroprevalence in Palestine persist low and is inadequate to provide herd immunity, emphasizing the need to maintain health measures to keep the outbreak under control. Population-based seroprevalence studies are to be conducted periodically to monitor the SARS-CoV-2 seroprevalence in Palestine and inform policy makers about the efficacy of their surveillance system.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by the Arab American UniversityAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Research is approved from the Helsinki Committee for Ethical Approval, Palestinian Health Research Council, Gaza, Palestine. Ethical approval number (PHRC/HC/737/20). Written informed consent was obtained from the 1355 adults from Palestinian households and approvals were obtained from Medicare laboratories for samples to be tested.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is available in the manuscript and supplementary tables